Drug Trial Radar · NCT06534892
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
10,212
Actual
Start
Aug 1, 2024
Primary completion
Sep 30, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vaccine, * To give the opportunity to participants who received only placebo in the RSVOA=ADJ- 006 study, to receive a dose of the RSVPreF3 OA vaccine and collect additional safety information.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA vaccineBiological
RSVPreF3 OA vaccine administered at different timepoints (revaccination groups) or for the first time (crossover group)
Primary outcomes
What the sponsor says the trial is designed to measure.
- RSV-A neutralizing titers expressed as Geometric mean titers (GMTs) in RSV_PreS4 group at Day 1Time frame: At Day 1
- RSV-A neutralizing titers expressed as GMTs in RSV_PreS4 group at Day 31Time frame: At Day 31
- RSV-B neutralizing titers expressed as GMTs in RSV_PreS4 group at Day 1Time frame: At Day 1
- RSV-B neutralizing titers expressed as GMTs in RSV_PreS4 group at Day 31Time frame: At Day 31
- RSV-A neutralizing titers expressed as Mean geometric increase (MGI) in RSV_PreS4 groupTime frame: From Day 1 to Day 31
- RSV-B neutralizing titers expressed as MGI in RSV_PreS4 groupTime frame: From Day 1 to Day 31
- Percentage of participants with RSV-A neutralizing titers greater than or equal to (>=) cut-off in RSV_PreS4 group at Day 1Time frame: At Day 1
- Percentage of participants with RSV-A neutralizing titers >= cut-off in RSV_PreS4 group at Day 31Time frame: At Day 31
- Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS4 group at Day 1Time frame: At Day 1
- Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS4 group at Day 31Time frame: At Day 31
- Percentage of participants with seroresponse rate (SRR) for RSV-A neutralizing titers in RSV_PreS4 groupTime frame: At Day 31
- Percentage of participants with SRR for RSV-B neutralizing titers in RSV_PreS4 groupTime frame: At Day 31
- RSV-A neutralizing titers expressed as GMT in RSV_PreS5 group at Day 1Time frame: At Day 1
- RSV-A neutralizing titers expressed as GMT in RSV_PreS5 group at Month 12Time frame: At Month 12
- RSV-A neutralizing titers expressed as GMT in RSV_PreS5 group at Month 13Time frame: At Month 13
- RSV-A neutralizing titers expressed as GMT in RSV_PreS5 group at Month 24Time frame: At Month 24
- RSV-B neutralizing titers expressed as GMTs in RSV_PreS5 group at Day 1Time frame: At Day 1
- RSV-B neutralizing titers expressed as GMTs in RSV_PreS5 group at Month 12Time frame: At Month 12
- RSV-B neutralizing titers expressed as GMTs in RSV_PreS5 group at Month 13Time frame: At Month 13
- RSV-B neutralizing titers expressed as GMTs in RSV_PreS5 group at Month 24Time frame: At Month 24
- RSV-A neutralizing titers expressed as MGI in RSV_PreS5 group from Month 12 to Month 13Time frame: From Month 12 to Month 13
- RSV-A neutralizing titers expressed as MGI in RSV_PreS5 group from Month 12 to Month 24Time frame: From Month 12 to Month 24
- RSV-B neutralizing titers expressed as MGI in RSV_PreS5 group from Month 12 to Month 13Time frame: From Month 12 to Month 13
- RSV-B neutralizing titers expressed as MGI in RSV_PreS5 group from Month 12 to Month 24Time frame: From Month 12 to Month 24
- Percentage of participants with RSV-A neutralizing titers >=cut-off in RSV_PreS5 group at Day 1Time frame: At Day 1
- Percentage of participants with RSV-A neutralizing titers >=cut-off in RSV_PreS5 group at Month 12Time frame: At Month 12
- Percentage of participants with RSV-A neutralizing titers >=cut-off in RSV_PreS5 group at Month 13Time frame: At Month 13
- Percentage of participants with RSV-A neutralizing titers >=cut-off in RSV_PreS5 group at Month 24Time frame: At Month 24
- Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS5 group at Day 1Time frame: At Day 1
- Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS5 group at Month 12Time frame: At Month 12
- Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS5 group at Month 13Time frame: At Month 13
- Percentage of participants with RSV-B neutralizing titers >=cut-off in RSV_PreS5 group at Month 24Time frame: At Month 24
- Percentage of participants with seroresponse rate (SRR) for RSV-A neutralizing titers in RSV_PreS5 groupTime frame: At Month 13
- Percentage of participants with SRR for RSV-B neutralizing titers in RSV_PreS5 groupTime frame: At Month 13
Locations
251 sites in 17 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Huntsville, Alabama
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Cerritos, California
GSK Investigational Site
Doral, Florida
GSK Investigational Site
Fort Myers, Florida
GSK Investigational Site
Jacksonville, Florida
GSK Investigational Site
Lake City, Florida
GSK Investigational Site
Melbourne, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Pinellas Park, Florida
GSK Investigational Site
The Villages, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Savannah, Georgia
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Evansville, Indiana
GSK Investigational Site
Mishawaka, Indiana
GSK Investigational Site
El Dorado, Kansas
GSK Investigational Site
Newton, Kansas
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
Rockville, Maryland
GSK Investigational Site
Richfield, Minnesota
GSK Investigational Site
Kansas City, Missouri
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
New York, New York
GSK Investigational Site
Rochester, New York
GSK Investigational Site
Hickory, North Carolina
GSK Investigational Site
Mooresville, North Carolina
GSK Investigational Site
Rocky Mount, North Carolina
GSK Investigational Site
Salisbury, North Carolina
GSK Investigational Site
Winston-Salem, North Carolina
GSK Investigational Site
Centerville, Ohio
Showing 40 of 251 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.